207 related articles for article (PubMed ID: 36934836)
1. Regulation of metabolism in pancreatic ductal adenocarcinoma via nanotechnology-enabled strategies.
Wang Z; Wu B; Nie G; Wei J; Li Y
Cancer Lett; 2023 Apr; 560():216138. PubMed ID: 36934836
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
3. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
4. Exploiting pancreatic cancer metabolism: challenges and opportunities.
De Santis MC; Bockorny B; Hirsch E; Cappello P; Martini M
Trends Mol Med; 2024 Jun; 30(6):592-604. PubMed ID: 38604929
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk Between Peripheral Innervation and Pancreatic Ductal Adenocarcinoma.
Ni B; Yin Y; Li Z; Wang J; Wang X; Wang K
Neurosci Bull; 2023 Nov; 39(11):1717-1731. PubMed ID: 37347365
[TBL] [Abstract][Full Text] [Related]
6. The interactive role of inflammatory mediators and metabolic reprogramming in pancreatic cancer.
Ohara Y; Valenzuela P; Hussain SP
Trends Cancer; 2022 Jul; 8(7):556-569. PubMed ID: 35525794
[TBL] [Abstract][Full Text] [Related]
7. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
8. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival.
Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A
Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927
[TBL] [Abstract][Full Text] [Related]
9. Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.
Liu YH; Hu CM; Hsu YS; Lee WH
Cell Death Dis; 2022 Sep; 13(9):817. PubMed ID: 36151074
[TBL] [Abstract][Full Text] [Related]
10. Targeting cancer cell metabolism in pancreatic adenocarcinoma.
Cohen R; Neuzillet C; Tijeras-Raballand A; Faivre S; de Gramont A; Raymond E
Oncotarget; 2015 Jul; 6(19):16832-47. PubMed ID: 26164081
[TBL] [Abstract][Full Text] [Related]
11. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
12. [A Review of Metabolic Stress and Development of Pancreatic Cancer].
Li JT; Lei MZ; Lei QY; Yin M
Sichuan Da Xue Xue Bao Yi Xue Ban; 2021 Jan; 52(1):5-10. PubMed ID: 33474881
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target.
Hartupee C; Nagalo BM; Chabu CY; Tesfay MZ; Coleman-Barnett J; West JT; Moaven O
Front Immunol; 2024; 15():1287459. PubMed ID: 38361931
[TBL] [Abstract][Full Text] [Related]
14. Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze.
Olivares O; Vasseur S
Int J Cancer; 2016 Feb; 138(4):787-96. PubMed ID: 25732227
[TBL] [Abstract][Full Text] [Related]
15. New Diagnostic and Therapeutic Aspects of Pancreatic Ductal Adenocarcinoma.
Mangge H; Niedrist T; Renner W; Lyer S; Alexiou C; Haybaeck J
Curr Med Chem; 2017; 24(28):3012-3024. PubMed ID: 28494747
[TBL] [Abstract][Full Text] [Related]
16. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
17. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment.
Boyd LNC; Andini KD; Peters GJ; Kazemier G; Giovannetti E
Semin Cancer Biol; 2022 Jul; 82():184-196. PubMed ID: 33737108
[TBL] [Abstract][Full Text] [Related]
19. Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness.
Rademaker G; Hennequière V; Brohée L; Nokin MJ; Lovinfosse P; Durieux F; Gofflot S; Bellier J; Costanza B; Herfs M; Peiffer R; Bettendorff L; Deroanne C; Thiry M; Delvenne P; Hustinx R; Bellahcène A; Castronovo V; Peulen O
Oncogene; 2018 Aug; 37(32):4398-4412. PubMed ID: 29720728
[TBL] [Abstract][Full Text] [Related]
20. Biomaterial substrate-derived compact cellular spheroids mimicking the behavior of pancreatic cancer and microenvironment.
Wong CW; Han HW; Tien YW; Hsu SH
Biomaterials; 2019 Aug; 213():119202. PubMed ID: 31132644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
